Physician

Five things our research uncovered when we recreated 16th century beer (and barrels)

Retrieved on: 
금요일, 4월 19, 2024

But why they did so and what their beer was like are questions shrouded in myth.

Key Points: 
  • But why they did so and what their beer was like are questions shrouded in myth.
  • Combining craft, microbiology, brewing science, archaeology, as well as history, this was the most comprehensive interdisciplinary study of historical beer ever undertaken.

1. People didn’t drink beer because water was unhealthy

  • It’s often assumed that lack of access to clean water led people to drink beer instead.
  • We know this isn’t true for many reasons, not least because brewers needed a constant source of fresh water to make the best beer.

2. Beer was a payment for work

  • Treatments for conditions such as flux or bed wetting, for example, required ground kid’s hoof or grated stag’s penis to be taken with a drink of beer.
  • At Christchurch Cathedral in Dublin, masons received up to 15 pints per day when undertaking heavy work.

3. Beer had some different ingredients then

  • The key ingredients were malt (made from barley or oats depending on the region), water, yeast and hops.
  • This resulted in a longer lasting drink, accelerating the development of the brewing industry as we know it today.
  • But there are differences between pre-modern and modern beers, relating primarily to the nature of the ingredients.

4. Making beer required skills in short supply today

  • Brewers were deeply in tune with their working conditions and didn’t have modern devices such as thermometers.
  • As the project team learned the hard way, small mistakes could be disastrous, resulting in spoiled beer and accidental porridge.
  • Recreating the technology of the past also highlighted the wider craft skills, such as coopering (making barrels), wicker-weaving, woodworking, and coppersmithing, that went into making all the equipment needed to make a pint.

5. Even everyday beer was strong

  • Based on little evidence, it is assumed that beer of around 2% alcohol by volume (abv) was the most common drink of the working classes.
  • Our experiment showed that a typical beer of middling strength actually had the potential to be around 5% abv, comparable to modern lager.
  • Those calls often came, however, from the same people who liberally supplied their workers with beer.


The FoodCult project is funded by the European Research Council (Grant Agreement 803486) Charlie Taverner also works as a policy lead for the food systems NGO, the Food, Farming and Countryside Commission.

Alcohol Addiction Treatment Firm will be Banned from Disclosing Health Data for Advertising to Settle FTC Charges that It Shared Data Without Consent

Retrieved on: 
금요일, 4월 12, 2024

The Federal Trade Commission has taken action against an alcohol addiction treatment service for allegedly disclosing users’ personal health data to third-party advertising platforms, including Meta and Google, for advertising without consumer consent, after promising to keep such information confidential.

Key Points: 
  • The Federal Trade Commission has taken action against an alcohol addiction treatment service for allegedly disclosing users’ personal health data to third-party advertising platforms, including Meta and Google, for advertising without consumer consent, after promising to keep such information confidential.
  • As part of a proposed order settling the FTC allegations, New York-based Monument, Inc. will be banned from disclosing health information for advertising and must obtain users’ affirmative consent before sharing health information with third parties for any other purpose.
  • “This action continues the FTC’s work to ensure strict limits on how firms handle sensitive health data, rather than putting the onus on consumers to protect themselves,” said Samuel Levine, Director of the FTC’s Bureau of Consumer Protection.
  • Monument used these pixels and APIs to track “standard” and “custom events,” meaning instances in which consumers interacted with Monument’s website.
  • If the company is found to have misrepresented its finances, it will be required to pay the full amount.
  • The Commission voted 3-0 to refer the complaint and stipulated final order to the Department of Justice for filing.
  • The DOJ filed the complaint and stipulated order in the U.S. District Court for the District of Columbia.

EQS-News: Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Retrieved on: 
수요일, 4월 10, 2024

BERKELEY, US – MAINZ, Germany – March 18th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.

Key Points: 
  • BERKELEY, US – MAINZ, Germany – March 18th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.
  • Designed for pharmacists, physicians, and healthcare professionals, this online training session aims to shed light on innovative laboratory diagnostic approaches for colorectal cancer screening.
  • Set against the backdrop of March's Colorectal Cancer Awareness Month, the webinar will delve into the significance of genetic markers and the advancements in screening techniques that offer a more accurate risk assessment and early detection.
  • Title: Darmkrebs-Früherkennung: Neue labordiagnostische Optionen (Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options)

EQS-News: APONTIS PHARMA expects profitable growth again in 2024

Retrieved on: 
수요일, 4월 10, 2024

APONTIS PHARMA closed the 2023 financial year with a consolidated net loss of EUR 11.3 million (2022: consolidated net income of EUR 2.7 million).

Key Points: 
  • APONTIS PHARMA closed the 2023 financial year with a consolidated net loss of EUR 11.3 million (2022: consolidated net income of EUR 2.7 million).
  • Bruno Wohlschlegel, Chief Executive Officer of APONTIS PHARMA AG: “The 2023 financial year was characterized by significant changes for APONTIS PHARMA.
  • Following the successful implementation of the performance and efficiency improvement program earlier than planned, APONTIS PHARMA has laid the foundations for future profitable growth in Single Pill combinations.
  • As such, we launched our 15th Single Pill combination on the German market in March and continue to see considerable growth potential for Single Pill combinations from APONTIS PHARMA.

EQS-News: Mainz Biomed Reports Full Year 2023 Financial Results

Retrieved on: 
수요일, 4월 10, 2024

ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million

Key Points: 
  • ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million
    BERKELEY, US – MAINZ, Germany – April 9, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today financial results for the fiscal year ended December 31, 2023.
  • “This past fiscal year represented an important period of progress for the Company highlighted by reporting results from our groundbreaking ColoFuture and eAArly DETECT studies which demonstrated extraordinary statistical significance for colorectal cancer (CRC) detection and advanced adenomas, a type of pre-cancerous polyp which are considered precursors to colorectal cancer” commented Guido Baechler, Chief Executive Officer of Mainz Biomed.
  • Final preparations for Pivotal FDA PMA clinical trial (ReconAAsense) evaluating gold standard self-administered CRC test - on track to commence patient enrollment in 2024.
  • Established commercial operations in major markets including Spain, Poland, Romania, Portugal, Israel, and the UK.

EQS-News: TVM CAPITAL LIFE SCIENCE TO PARTICIPATE IN LSI USA ’24 EMERGING MEDTECH SUMMIT 2024

Retrieved on: 
수요일, 4월 10, 2024

Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 18-22, 2024, in Dana Point, California, USA.
  • "Medtech innovation continues to be at the forefront of healthcare advancement, driving transformative changes in patient care, operational efficiency and cost reduction.
  • As part of our commercial-stage medical technologies investment strategy, TVM seeks breakthrough solutions that align with emerging trends and could redefine the standard of care.

Global Experts from SEPA Call for the Control of Gingivitis Rather than Waiting for Periodontitis to Develop

Retrieved on: 
월요일, 4월 8, 2024

SEPA: Limited knowledge among oral health teams of the recommendations and evidence currently available on oral antiseptics (that are clinically proven to be effective) reduces their implementation; therefore, more practical and simple advice is proposed.

Key Points: 
  • This was highlighted at an International Summit of Experts held at the Casa de las Encías in Madrid, Spain, the headquarters of the SEPA Foundation.
  • "Periodontal diseases are prevalent worldwide, affecting hundreds of millions of people," says the meeting coordinator, Dr. Paula Matesanz, vice president of SEPA.
  • As Dr. Iain Chapple summarizes, "It is time for a paradigm shift: we must control gingivitis and not wait until periodontitis develops."
  • J Clin Periodontol 2022 Jun:49 Suppl 24:4-71 (version adapted by SEPA available at https://portal.guiasalud.es/gpc/tratamiento-periodontitis-estadio-iv )
    * Chapple I, Time to take gum disease seriously.

Oberheiden P.C. Welcomes Former Federal Prosecutor Jennifer W. Corinis as New Litigation Counsel

Retrieved on: 
금요일, 3월 15, 2024

, a premier Dallas-based litigation and compliance firm, proudly announces the addition of Jennifer W. Corinis to its team as Litigation Counsel.

Key Points: 
  • , a premier Dallas-based litigation and compliance firm, proudly announces the addition of Jennifer W. Corinis to its team as Litigation Counsel.
  • With a distinguished 25-year career that spans across various sectors of the legal system, Corinis brings a wealth of experience and expertise, particularly in federal civil and criminal litigation, as well as appeals.
  • Before joining Oberheiden P.C., Jennifer W. Corinis dedicated 14 years of her career to serving as a federal prosecutor, where she honed her skills in the courtroom, successfully trying a dozen federal cases on behalf of the United States and arguing numerous cases before the United States Court of Appeals.
  • Throughout her illustrious career, Corinis has achieved notable successes in defending federal agencies, companies, and individuals in high-stakes litigation.

Neusoft Xikang Holdings Inc. Releases 2023 Annual Results, Business Structure Gradually Optimized, Share of Medical Services Business Continued to Grow

Retrieved on: 
수요일, 3월 20, 2024

In 2023, internet medical services were more widely recognized and developed rapidly, and digital healthcare services are becoming a regularised healthcare option for the public.

Key Points: 
  • In 2023, internet medical services were more widely recognized and developed rapidly, and digital healthcare services are becoming a regularised healthcare option for the public.
  • In 2023, online medical services provided by city-level online hospitals in Ningbo accounted for 53% of the total services in the city.
  • At the same time, the Group continued to optimize the medical service process, constantly diversified scenarios and content of online medical services, leading to a significant increase in customer services.
  • The focus will be on the coordinated development of "Medical + Nursing + Health" service business, providing users with more sustainable, convenient, and high-quality medical and health services.